NDAORALGRANULE
Approved
Sep 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
ALKINDI SPRINKLE (hydrocortisone) by PharmaIN is corticosteroid hormone receptor agonists [moa]. Approved for the following conditions, rheumatoid arthritis, rheumatoid arthritis and 8 more indications. First approved in 2020.
Drug data last refreshed 3h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALKINDI SPRINKLE is an oral hydrocortisone granule formulation approved in 2020 for pediatric adrenal insufficiency and multiple inflammatory/immune conditions including rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, ulcerative colitis, and hematologic malignancies. It is a corticosteroid hormone receptor agonist that exerts anti-inflammatory and immunosuppressive effects across multiple organ systems. The sprinkle formulation enables flexible dosing and improved pediatric compliance compared to traditional tablets.
Peak7.9 years to LOE
Product is in peak commercial lifecycle with approximately 7.9 years of patent protection remaining; commercial teams should expect sustained revenue performance with transition planning beginning around 2032.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (9)
Worked on ALKINDI SPRINKLE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.